NCT01364155View on ClinicalTrials.gov

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

PHASE2UnknownINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Impaired Glucose ToleranceInsulin Resistance

Interventions

DRUG

LIM-0705

DRUG

Placebo capsules

Trial Locations (1)

91911

RECRUITING

Profil Institute of Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

Limerick BioPharma

All Listed Sponsors

lead

Limerick BioPharma

INDUSTRY